RFXAP

RFXAP is an essential subunit of the trimeric RFX transcription factor complex (with RFX5 and RFXB) that binds X-box elements in MHC class II promoters, and its loss causes group D MHC-II deficiency (PMID:9118943, PMID:9287230). Mechanistically, the intrinsically disordered C-terminal domain of RFXAP folds into two α-helices upon binding the antiparallel coiled-coil dimerization 'staple' formed by two RFX5 N-terminal helices, generating an RFX5–RFXAP module that then recruits RFXB with high affinity to establish an ordered assembly pathway (PMID:19274739, PMID:20732328); both RFXAP and RFXB are required to relieve autoinhibition of RFX5 DNA binding and allow the complex to occupy the proximal MHC-II promoter (PMID:18723135). The conserved C-terminal residues of RFXAP — including hydrophobic positions and phosphorylatable sites — mediate isotype-specific transcriptional output by controlling promoter occupancy and recruitment of the co-activator CIITA, such that distinct C-terminal segments are differentially required for HLA-DR versus HLA-DQ and HLA-DP expression (PMID:11486010, PMID:16337482). Beyond MHC-II regulation, RFXAP directly binds and transcriptionally activates the histone demethylase KDM4A in pancreatic cancer cells, reducing H3K36 methylation, impairing DNA repair, and sensitizing cells to DNA damage (PMID:33093461). RFXAP expression is itself post-transcriptionally controlled by miR-212-3p, which directly targets RFXAP mRNA to suppress MHC-II and induce immune tolerance, and which is repressed by IFN-γ to drive RFXAP induction (PMID:26337469, PMID:29467893).

1. 1997 High

   Established that RFXAP is a distinct, essential subunit of the RFX DNA-binding complex whose loss causes a defined MHC-II deficiency, defining the gene's core requirement for MHC-II expression.

   Evidence Complementation rescue by transfection of wild-type RFXAP into patient cell lines with RFX-binding and MHC-II readouts

   PMID:9118943 PMID:9287230

   Open questions at the time

   • Did not resolve how RFXAP contributes structurally to the complex
   • Did not define the functional domains within RFXAP
2. 2001 High

   Mapped function to the RFXAP C-terminal domain and revealed isotype-specific requirements, showing the protein does more than serve as a uniform scaffold.

   Evidence Deletion/domain-mapping complementation in RFXAP-deficient cells with in vivo promoter occupancy and CIITA recruitment assays

   PMID:11486010

   Open questions at the time

   • Did not identify the specific residues mediating the isotype distinction
   • Mechanism of differential CIITA recruitment unresolved
3. 2005 High

   Pinpointed conserved hydrophobic and phosphorylatable C-terminal residues as the determinants of complex formation, DNA binding, and CIITA recruitment, linking sequence to coordinate isotype regulation.

   Evidence Site-directed mutagenesis with complementation, in vivo ChIP, and chimeric reporter assays in BLS cell lines

   PMID:16337482

   Open questions at the time

   • Whether phosphorylation actually occurs and which kinase acts is not established
   • No structural basis for the residue requirements yet
4. 2008 Medium

   Defined the functional logic of the trimeric complex by showing RFXAP and RFXB together relieve RFX5 autoinhibition to enable promoter binding.

   Evidence EMSA with purified RFX5, RFXAP, and RFXB plus domain-deletion analysis

   PMID:18723135

   Open questions at the time

   • In vitro EMSA single method; no structural detail of the autoinhibited state
   • Did not show conformational changes directly
5. 2008 Medium

   Demonstrated that non-coding regulation of RFXAP itself can cause MHC-II deficiency, expanding the disease mechanism to promoter-level loss of expression.

   Evidence Promoter reporter assay and RNA Pol II ChIP in a patient cell line carrying a 5'-UTR insertion

   PMID:18336911

   Open questions at the time

   • Single patient; generalizability unknown
   • Mechanism by which the insertion blocks Pol II recruitment not defined
6. 2009 High

   Resolved the assembly mechanism by showing the disordered RFXAP C-terminus folds upon binding RFX5 and licenses high-affinity RFXB recruitment, defining an ordered pathway.

   Evidence NMR, circular dichroism, and isothermal titration calorimetry on isolated RFXAP_C and RFX5_N

   PMID:19274739

   Open questions at the time

   • Atomic-resolution structure of the interface not yet determined
   • Role of full-length proteins and DNA in assembly not addressed
7. 2009 Medium

   Confirmed in a lymphoma context that C-terminal frameshift loss abolishes coordinate MHC-II expression and is rescuable, reinforcing the C-terminus as functionally indispensable.

   Evidence Sequencing and stable-transfection complementation with surface MHC-II analysis in OCI-Ly2 DLBCL cells

   PMID:20024540

   Open questions at the time

   • Single cell line
   • Did not dissect which C-terminal interactions were lost
8. 2010 High

   Provided the high-resolution structural basis: RFXAP_C forms a V-shaped helix pair packing into the RFX5 antiparallel coiled-coil staple, with a predicted RFXB-binding surface.

   Evidence Solution NMR structure of the RFX5_N2–RFXAP_C complex with mutagenesis of interface leucines

   PMID:20732328

   Open questions at the time

   • The full trimeric RFX5–RFXAP–RFXB structure not solved
   • Direct structural proof of RFXB contact site lacking
9. 2015 Medium

   Identified post-transcriptional control of RFXAP by tumor-derived exosomal miR-212-3p, linking RFXAP suppression to immune tolerance in dendritic cells.

   Evidence miR-212-3p mimic/inhibitor transfection into dendritic cells with RFXAP and MHC-II readouts

   PMID:26337469

   Open questions at the time

   • Direct 3'-UTR targeting not formally validated in this study
   • In vivo relevance of exosomal transfer not established here
10. 2018 Medium

    Placed miR-212-3p downstream of IFN-γ and upstream of RFXAP, establishing a cytokine-controlled axis governing RFXAP and MHC-II levels.

    Evidence IFN-γ dose-response, luciferase reporter of the RFXAP 3'-UTR, and epistasis with miR-212-3p mimics in pancreatic cancer cells

    PMID:29467893

    Open questions at the time

    • Single lab; how IFN-γ represses miR-212-3p not defined
    • Physiological setting beyond pancreatic cancer cells untested
11. 2020 Medium

    Revealed an MHC-II-independent function: RFXAP directly activates KDM4A transcription, reducing H3K36 methylation and modulating DNA repair and damage sensitivity.

    Evidence ChIP-seq, dual-luciferase reporter, gain/loss-of-function, and xenograft model in pancreatic cancer cells

    PMID:33093461

    Open questions at the time

    • Whether RFXAP acts here within the RFX complex or independently is unknown
    • Generality beyond pancreatic cancer cells not established

• How RFXAP integrates its canonical MHC-II co-activator role with the newly described KDM4A/chromatin and cytokine-miRNA regulatory axes — including whether phosphorylation modulates its activity and whether it engages non-MHC-II targets within or outside the RFX complex — remains open.
• No kinase or phosphorylation event on RFXAP directly demonstrated
• No full trimeric RFX–DNA structure
• Mechanistic link between MHC-II and KDM4A functions undefined